Enterprise Value

2.011B

Cash

175.3M

Avg Qtr Burn

N/A

Short % of Float

12.80%

Insider Ownership

1.62%

Institutional Own.

-

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Linzess® (linaclotide) Details
Irritable bowel syndrome, Inflammatory bowel disease, Bowel disorder

Approved

Quarterly sales

Approved

Quarterly sales

Apraglutide Details
Inflammatory bowel disease, Bowel disorder

Big Mover™

Susp. Mover™

Phase 3

Data readout

Apraglutide (agonist of the GLP-2 receptor) Details
Short bowel syndrome

Big Mover™

Susp. Mover™

Phase 3

Data readout

IW-3300 Details
Endometriosis, Visceral pain, Interstitial cystitis/bladder pain syndrome

Phase 2

Data readout

Phase 2

Data readout

Apraglutide Details
Graft-versus-host disease

Phase 2

Data readout

Apraglutide (agonist of the GLP-2 receptor) Details
Short bowel syndrome, Short bowel syndrome with colon-in-continuity

Phase 2

Update

CNP-104 Details
Primary biliary cholangitis, Liver disease, Autoimmune disease

Phase 2a

Data readout

Linaclotide Details
Irritable bowel syndrome, Inflammatory bowel disease, Bowel disorder, Constipation

Failed

Discontinued